Scientists of the Institute of Research Research in Göttingen (Germany) found out that the oomikron-option of coronavirus is resistant to the main antibodies. This is reported in an article published in Cell magazine.
Researchers have shown that antibodies of recovered people practically do not inhibit the oomikron option. The antibodies after two Biontech-Pfizer vaccinations also showed significantly reduced efficacy, but after a third dose, the effectiveness is to some extent restored. The oxford-Astrazeneca and Biontech-Pfizer heterologous vaccination is also characterized by increased protection against the omicron strain.
SARS-COV-2 seems to spread faster than any previous strain, and soon can dominate the world. SARS-COV-2 infection and vaccination lead to the production of antibodies, which largely contribute to the protection against severe disease, despite the reduced neutralizing ability of the antibodies.
Currently, COVID-19 is used by Czirivimab and Imgevimab antibodies, Etiesemab and Bamlanyvimab. However, scientists have shown that these antibodies are largely ineffective against Oomikron S-protein. At the same time, swelling is an exception and can be useful for the treatment of coronavirus infection.